Company Information

Agenus is an immuno-oncology company focused on the discovery and development of revolutionary new treatments that engage the body’s immune system to benefit patients suffering from cancer. By combining multiple powerful platforms, Agenus has established a highly integrated approach for the discovery, development and manufacture of monoclonal antibodies that modulate targets of interest. In addition, the Company’s cancer vaccine program includes three proprietary platforms focused on individualized and off-the-shelf vaccines uniquely designed for each patient. Agenus’ broad portfolio of novel checkpoint and other immuno-modulatory monoclonal antibodies, vaccines and adjuvants, work in combination to provide the opportunity to create best-in-class therapeutic regimens. The Company has formed collaborations with Merck and Incyte to discover and develop multiple checkpoint antibodies.

 

Press Releases
Jun 20, 2018

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies1 invites investors and the general public to...

Jun 12, 2018

A study published in Cancer Cell reports on a novel discovery made by Agenus Inc. (NASDAQ: AGEN) that may enhance the immune activity of cancer fighting antibodies, including those targeting...

Jun 6, 2018

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies1, announced today that Jennifer Buell, Ph.D.,...

VIEW ALL PRESS RELEASES

Stock Chart
NASDAQAGEN
Events and Presentations
Wednesday, June 20, 2018
5:00pm - 6:00pm EDT
Thursday, June 7, 2018
4:30pm - 4:55pm EDT
Tuesday, May 8, 2018
12:50pm - 1:25pm EDT

“the